Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
KLRD1 - Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
UPK2 - Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
LOC100506860 - Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
PMCHL1 - Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
FOXL1 - Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
LINC01019 - Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
MIRLET7BHG - Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
CR1 - Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
HYAL4 - Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
DYNLRB1 - Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
EMCN - Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
FBLIM1 - Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
PRMT5-AS1 - Multiple myeloma cell lines with acquired resistance to chemotherapeutic agent carfilzomib
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on